# Novel drugs for older patients with acute myeloid leuke

Leukemia

29, 760-769

DOI: 10.1038/leu.2014.244

Citation Report

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | Panobinostat as part of induction and maintenance for elderly patients with newly diagnosed acute myeloid leukemia: phase Ib/II panobidara study. Haematologica, 2015, 100, 1294-1300. | 1.7 | 27 |
| 2 | The interplay of autophagy and Î²-Catenin signaling regulates differentiation in acute myeloid leukemia. Cell Death Discovery, 2015, 1, 15031. | 2.0 | 26 |
| 3 | Myelodysplastic syndromes: 2015 Update on diagnosis, riskâ€stratification and management. American Journal of Hematology, 2015, 90, 831-841. | 2.0 | 101 |
| 4 | Volasertib for AML: clinical use and patient consideration. OncoTargets and Therapy, 2015, 8, 1761. | 1.0 | 13 |
| 5 | Idarubicin, cytarabine, and pravastatin as induction therapy for untreated acute myeloid leukemia and highâ€risk myelodysplastic syndrome. American Journal of Hematology, 2015, 90, 483-486. | 2.0 | 21 |
| 6 | Design of FLT3 Inhibitor - Gold Nanoparticle Conjugates as Potential Therapeutic Agents for the Treatment of Acute Myeloid Leukemia. Nanoscale Research Letters, 2015, 10, 466. | 3.1 | 29 |
| 7 | The ferroptosis inducer erastin enhances sensitivity of acute myeloid leukemia cells to chemotherapeutic agents. Molecular and Cellular Oncology, 2015, 2, e1054549. | 0.3 | 301 |
| 8 | ARHGEF3 controls HDACi-induced differentiation via RhoA-dependent pathways in acute myeloid leukemias. Epigenetics, 2015, 10, 6-18. | 1.3 | 29 |
| 10 | BCL-2 is dispensable for thrombopoiesis and platelet survival. Cell Death and Disease, 2015, 6, e1721-e1721. | 2.7 | 68 |
| 11 | Novel Therapeutics for Therapy-Related Acute Myeloid Leukemia: 2014. Clinical Lymphoma, Myeloma and Leukemia, 2015, 15, S91-S93. | 0.2 | 10 |
| 12 | Drugging the unfolded protein response in acute leukemias. Journal of Hematology and Oncology, 2015, 8, 87. | 6.9 | 22 |
| 14 | Metabolomics profiles delineate uridine deficiency contributes to mitochondria-mediated apoptosis induced by celastrol in human acute promyelocytic leukemia cells. Oncotarget, 2016, 7, 46557-46572. | 0.8 | 24 |
| 15 | Prognostic and therapeutic role of targetable lesions in B-lineage acute lymphoblastic leukemia without recurrent fusion genes. Oncotarget, 2016, 7, 13886-13901. | 0.8 | 20 |
| 16 | Therapeutic Resistance in Acute Myeloid Leukemia: The Role of Non-Coding RNAs. International Journal of Molecular Sciences, 2016, 17, 2080. | 1.8 | 58 |
| 17 | Quantitative proteomic analysis of histone modifications in decitabine sensitive and resistant leukemia cell lines. Clinical Proteomics, 2016, 13, 14. | 1.1 | 11 |
| 19 | Cabozantinib is selectively cytotoxic in acute myeloid leukemia cells with FLT3-internal tandem duplication (FLT3-ITD). Cancer Letters, 2016, 376, 218-225. | 3.2 | 28 |
| 20 | Panobinostat for the treatment of acute myelogenous leukemia. Expert Opinion on Investigational Drugs, 2016, 25, 1117-1131. | 1.9 | 23 |
| 21 | NKCT1 (purified Naja kaouthia protein toxin) conjugated gold nanoparticles induced Akt/mTOR inactivation mediated autophagic and caspase 3 activated apoptotic cell death in leukemic cell. Toxicon, 2016, 121, 86-97. | 0.8 | 19 |

| # | Article | IF | Citations |
|---|---|---|---|
| 22 | The role of the gastrointestinal microbiome in infectious complications during induction chemotherapy for acute myeloid leukemia. Cancer, 2016, 122, 2186-2196. | 2.0 | 121 |
| 23 | Targeting transcription factors by small compoundsâ€"Current strategies and future implications. Biochemical Pharmacology, 2016, 107, 1-13. | 2.0 | 69 |
| 24 | Role of drug transport and metabolism in the chemoresistance of acute myeloid leukemia. Blood Reviews, 2016, 30, 55-64. | 2.8 | 39 |
| 25 | Anti-mitotic agents: Are they emerging molecules for cancer treatment?. , 2017, 173, 67-82. | | 55 |
| 26 | Characterization of oral and gut microbiome temporal variability in hospitalized cancer patients. Genome Medicine, 2017, 9, 21. | 3.6 | 80 |
| 27 | Low-dose lenalidomide plus cytarabine in very elderly, unfit acute myeloid leukemia patients: Final result of a phase II study. Leukemia Research, 2017, 62, 77-83. | 0.4 | 15 |
| 28 | Inhibition of Suicidal Erythrocyte Death by Volasertib. Cellular Physiology and Biochemistry, 2017, 43, 1472-1486. | 1.1 | 10 |
| 30 | Targeting acute myeloid leukemia with TP53-independent vosaroxin. Future Oncology, 2017, 13, 125-133. | 1.1 | 5 |
| 31 | Immunotherapy in Pediatric Acute Leukemia: A Novel Magic Bullet or an Illusory Hope?. , 0, , . | | 0 |
| 32 | Efficacy and safety of decitabine in treatment of elderly patients with acute myeloid leukemia: A systematic review and meta-analysis. Oncotarget, 2017, 8, 41498-41507. | 0.8 | 58 |
| 33 | Establishment of a high-throughput detection system for DNA demethylating agents. Epigenetics, 2018, 13, 147-155. | 1.3 | 10 |
| 34 | Myelodysplastic syndromes: 2018 update on diagnosis, riskâ€stratification and management. American Journal of Hematology, 2018, 93, 129-147. | 2.0 | 154 |
| 35 | Overexpression of TEL-MN1 Fusion Enhances Resistance of HL-60 Cells to Idarubicin. Chemotherapy, 2018, 63, 308-314. | 0.8 | 1 |
| 36 | Natural Products as Sources of Anticancer Agents: Current Approaches and Perspectives. , 2018, , 309-331. | | 10 |
| 37 | Therapy-Related Acute Myelogenous Leukemia. , 2018, , 465-482. | | 0 |
| 38 | Therapeutic Antibodies for Myeloid Neoplasmsâ€"Current Developments and Future Directions. Frontiers in Oncology, 2018, 8, 152. | 1.3 | 30 |
| 39 | Inhibition of protein disulfide isomerase induces differentiation of acute myeloid leukemia cells. Haematologica, 2018, 103, 1843-1852. | 1.7 | 8 |
| 40 | Advances in treatment formulations for acute myeloid leukemia. Drug Discovery Today, 2018, 23, 1936-1949. | 3.2 | 40 |

| # | Article | IF | Citations |
|---|---|---|---|
| 41 | New drugs in AML: uses and abuses. Leukemia, 2018, 32, 1479-1481. | 3.3 | 12 |
| 42 | Realâ€world experience with decitabine as a firstâ€line treatment in 306 elderly acute myeloid leukaemia patients unfit for intensive chemotherapy. Hematological Oncology, 2019, 37, 447-455. | 0.8 | 25 |
| 43 | Exploiting metabolic vulnerabilities for personalized therapy in acute myeloid leukemia. BMC Biology, 2019, 17, 57. | 1.7 | 31 |
| 44 | Oncoprotein Inhibitor Rigosertib Loaded in ApoE-Targeted Smart Polymersomes Reveals High Safety and Potency against Human Glioblastoma in Mice. Molecular Pharmaceutics, 2019, 16, 3711-3719. | 2.3 | 32 |
| 45 | Pilot Study on the Cost of Some Oncohematology Diseases in Bulgaria. Frontiers in Public Health, 2019, 7, 70. | 1.3 | 2 |
| 46 | HDAC Inhibitors in Acute Myeloid Leukemia. Cancers, 2019, 11, 1794. | 1.7 | 118 |
| 47 | A glimmer of hope for older people with acute myeloid leukaemia. Lancet Haematology,the, 2020, 7, e700-e701. | 2.2 | 0 |
| 48 | Targeting Pharmacokinetic Drug Resistance in Acute Myeloid Leukemia Cells with CDK4/6 Inhibitors. Cancers, 2020, 12, 1596. | 1.7 | 13 |
| 49 | LT-171-861, a novel FLT3 inhibitor, shows excellent preclinical efficacy for the treatment of FLT3 mutant acute myeloid leukemia. Theranostics, 2021, 11, 93-106. | 4.6 | 13 |
| 50 | Targeting LSD1 for acute myeloid leukemia (AML) treatment. Pharmacological Research, 2021, 164, 105335. | 3.1 | 44 |
| 51 | The role of CD44 in cancer chemoresistance: A concise review. European Journal of Pharmacology, 2021, 903, 174147. | 1.7 | 49 |
| 52 | Zwitterion-functionalized hollow mesoporous Prussian blue nanoparticles for targeted and synergetic chemo-photothermal treatment of acute myeloid leukemia. Journal of Materials Chemistry B, 2021, 9, 5245-5254. | 2.9 | 15 |
| 53 | Epimutational profile of hematologic malignancies as attractive target for new epigenetic therapies. Oncotarget, 2016, 7, 57327-57350. | 0.8 | 24 |
| 54 | Azacitidine or intensive chemotherapy for older patients with secondary or therapy-related acute myeloid leukemia. Oncotarget, 2017, 8, 79126-79136. | 0.8 | 30 |
| 55 | Cancer-selective cytotoxic Ca2+ overload in acute myeloid leukemia cells and attenuation of disease progression in mice by synergistically acting polyphenols curcumin and carnosic acid. Oncotarget, 2016, 7, 31847-31861. | 0.8 | 52 |
| 56 | Development of personalized molecular therapy for acute myeloid leukemia. Current Pharmaceutical Biotechnology, 2015, 17, 20-29. | 0.9 | 4 |
| 57 | Gold Nanorods Exhibit Intrinsic Therapeutic Activity via Controlling N6-Methyladenosine-Based Epitranscriptomics in Acute Myeloid Leukemia. ACS Nano, 2021, 15, 17689-17704. | 7.3 | 36 |
| 58 | Akute LeukÃmien des Erwachsenen. , 2016, , 119-133. | | 0 |

| # | Article | IF | Citations |
|---|---|---|---|
| 59 | Hypomethylating Agents in Oncohematology. Klinicheskaya Onkogematologiya/Clinical Oncohematology, 2016, 9, 369-382. | 0.1 | 2 |
| 61 | Purine-based anticancer drugs. , 2022, , 69-105. | | 1 |
| 62 | The Increase in the Drug Resistance of Acute Myeloid Leukemia THP-1 Cells in High-Density Cell Culture Is Associated with Inflammatory-like Activation and Anti-Apoptotic Bcl-2 Proteins. International Journal of Molecular Sciences, 2022, 23, 7881. | 1.8 | 6 |
| 63 | HDAC inhibitors suppress protein poly(ADP-ribosyl)ation and DNA repair protein levels and phosphorylation status in hematologic cancer cells: Implications for their use in combination with PARP inhibitors and chemotherapeutic drugs. Oncotarget, 2022, 13, 1122-1135. | 0.8 | 5 |